Similar articles

• Safety and efficacy of pegylated interferon alpha-2a and ribavirin for the treatment of hepatitis C in patients with thalassemia.

  Harmatz P, Jonas MM, Kwiatkowski JL, Wright EC, Fischer R, Vichinsky E, Giardina PJ, Neufeld EJ, Porter J, Olivieri N; Thalassemia Clinical Research Network. Harmatz P, et al. Haematologica. 2008 Aug;93(8):1247-51. doi: 10.3324/haematol.12352. Epub 2008 Jun 12. Haematologica. 2008. PMID: 18556414 Clinical Trial.
• [Treatment with pegylated interferon and ribavirin in patients co-infected by human immunodeficiency virus and hepatitis C virus].

  Marcos Sánchez F, Albo Castaño MI, Casallo Blanco S. Marcos Sánchez F, et al. Rev Clin Esp. 2007 Mar;207(3):150-1; author reply 151-2. Rev Clin Esp. 2007. PMID: 17397643 Spanish. No abstract available.
• [Hepatitis C].

  Pache I, Gonvers JJ. Pache I, et al. Rev Med Suisse Romande. 2002 Oct;122(10):507-12. Rev Med Suisse Romande. 2002. PMID: 12494784 French. No abstract available.
• [Long-acting interferon: studies on pegylated interferon].

  Ma H, Wang H. Ma H, et al. Zhonghua Gan Zang Bing Za Zhi. 2002 Feb;10(1):78-9. Zhonghua Gan Zang Bing Za Zhi. 2002. PMID: 11856520 Review. Chinese. No abstract available.
• [Drug therapy of hepatitis B and C].

  Färkkilä M. Färkkilä M. Duodecim. 2003;119(6):519-29. Duodecim. 2003. PMID: 12708339 Review. Finnish. No abstract available.